Dronabinol
- Generic Name
- Dronabinol
- Brand Names
- Marinol, Sativex, Syndros
- Drug Type
- Small Molecule
- Chemical Formula
- C21H30O2
- CAS Number
- 1972-08-3
- Unique Ingredient Identifier
- 7J8897W37S
- Background
Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased ...
- Indication
Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
- Associated Conditions
- Anorexia, Chemotherapy-Induced Nausea and Vomiting
- Associated Therapies
- -
Responses to Marijuana-Related Cues Versus Neutral Cues in Adults Taking Tetrahydrocannabinol (THC) - 2
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Wayne State University
- Target Recruit Count
- 20
- Registration Number
- NCT00218504
- Locations
- 🇺🇸
Wayne State University, Detroit, Michigan, United States
Use of Cannabinoids in Patients With Multiple Sclerosis
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-11-29
- Lead Sponsor
- S. Andrea Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00202423
- Locations
- 🇮🇹
Department of Neurology- University of Rome la Sapienza, Rome, Italy
Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS
- Conditions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 30
- Registration Number
- NCT00079560
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-25
- Target Recruit Count
- 56
- Registration Number
- NCT00000737
- Locations
- 🇺🇸
Denver Public Health Dept, Denver, Colorado, United States
🇺🇸Univ of Illinois, Chicago, Illinois, United States
🇺🇸Univ of Kansas School of Medicine, Wichita, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.